Sam Chun Dang Pharm announced on the 25th an exclusive distribution agreement for the Eylea biosimilar with nine Western European countries (UK, Belgium, Netherlands, Norway, Portugal, Sweden, Greece, Ireland, and Finland).

Under the agreement, Sam Chun Dang Pharm will receive 55% of the partnering company’s net sales, further strengthening its presence in the European market. Sam Chun Dang Pharm has established a sales network in the UK, Germany, Spain, and Italy, and the current agreement has established a stepping stone for entering the UK market, which is the biggest market in Europe:

“Sam Chun Dang Pharm was able to sign the agreement on the most favorable terms as we rec